Related Experiment Video
Updated: Jan 14, 2026

07:51
Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
904
Infliximab-Induced Organizing Pneumonia Resulting in Persistent Respiratory Impairment.
1Department of Internal Medicine, The Vancouver Clinic and Legacy Salmon Creek Medical Center, Vancouver, WA.
ACG Case Reports Journal
|October 20, 2025
Summary
Infliximab treats ulcerative colitis but may cause lung injury. This study investigates severe infliximab-induced pneumonitis and its long-term respiratory effects, which are currently poorly understood.
Area of Science:
- Pulmonology
- Gastroenterology
- Immunology
Background:
- Infliximab is a biologic agent targeting TNF cytokine signaling for moderate-to-severe ulcerative colitis.
- TNF inhibitors can cause immune suppression and impair tissue repair.
- Case reports suggest infliximab is linked to acute pulmonary toxicity.
Related Concept Videos
Pneumonia IV: Management
751
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
751
Pneumonia II: Pathophysiology
2.6K
The pathophysiology of pneumonia involves the following steps:
2.6K
Pneumonia I: Introduction
723
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
723
Drugs Used in Lower Respiratory Disorders: Overview
1.0K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.0K
Pneumonia III: Complications and Assessment
777
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
777
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
3.5K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
3.5K

